| Literature DB >> 28070617 |
S Jongen1, A Vermeeren2, N N J J M van der Sluiszen2, M B Schumacher3, E L Theunissen2, K P C Kuypers2, E F P M Vuurman2, J G Ramaekers2.
Abstract
INTRODUCTION: The on-the-road highway driving test is generally regarded as a gold standard for assessing drug-induced driving impairment. The primary outcome measure is the standard deviation of lateral position (SDLP), a measure of road tracking error or "weaving". The test has been calibrated for incremental doses of alcohol almost 30 years ago in order to define the impact of drug-induced impairment in terms of blood alcohol concentration (BAC) equivalents. Drug-induced changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant ever since. The present analysis was conducted to assess the robustness of the alcohol effect in a range of on-the-road driving studies which have been conducted since the initial alcohol calibration study.Entities:
Keywords: Alcohol; Clinical relevance; On-the-road driving; Standard deviation of lateral position
Mesh:
Substances:
Year: 2017 PMID: 28070617 PMCID: PMC5306436 DOI: 10.1007/s00213-016-4519-z
Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN: 0033-3158 Impact factor: 4.530
Fig. 2Standardized highway driving test. a Participants drive a specially instrumented vehicle for about 1 h over a 100 km primary highway circuit, accompanied by a licensed driving instructor having access to dual controls. The participants’ task is to drive with a steady lateral position between the delineated boundaries of the slower right traffic lane, while maintaining a constant speed of 95 km/h. b The standard deviation of lateral position (SDLP in centimeter) is an index of road tracking error or “weaving”. c The relationship between blood alcohol concentration and SDLP as obtained by Louwerens et al. (1987)
Summary of nine studies included in the pooled analysis. All studies were conducted following a double-blind crossover design
| Study | Sample size | Age range (y) | Alcohol dosing | Time of dosing until start driving test | Time of testing | BAC start driving-BAC end driving (in g/L) |
|---|---|---|---|---|---|---|
| Ramaekers et al. | All 16a | 22–35 | 0.72 g/kg | 3 h | Noon | 0.37–0.20 |
| Vermeeren and O’Hanlon | All 24 | 22–44 | 7 constant 5.6 g, a 10 g, and 2 adjustable doses | 3 h | Noon | 0.45–0.37 |
| Ramaekers et al. | All 18a | 20–28 | 0.60 g/kg | 1.5 h | Evening | 0.50–0.35 |
| Vermeeren et al. | All 19 | 21–45 | Males 0.43 g/kg | 1 h | Morning | 0.42–0.23 |
| Vermeeren et al. | All 30 | 21–45 | Males 0.43 g/kg | 2.15 h | Noon | 0.37–0.24 |
| Kuypers et al. | All 18 | 20–37 | 0.70 g/kg | 2 h | Noon | 0.37–0.29 |
| van der Sluiszen et al. | All 25 | 21–45 | Males 3 doses (0.23, 0.14, 0.14 g/kg) | 1 h | Noon | 0.45–0.30 |
| Schumacher et al. | All 17 | 23–58 | Males 3 doses (0.23, 0.14, 0.14 g/kg) | 1 h | Morning | 0.49–0.39 |
| Schumacher | All 15 | 23–59 | Males 3 doses (0.23, 0.14, 0.14 g/kg) | 1 h | Morning | 0.50–0.35 |
BAC blood alcohol concentration
aNo gender data available
Fig. 1Formulas for calculating blood alcohol concentrations
Overall mean (SD) score of standard deviation of lateral position (SDLP) after placebo (PBO) and alcohol (ALC), mean (95% CI) change scores (Δ SDLP), repeated measure analyses of variance, Dunlap’s effect sizes and proportion improved vs. impaired driver, and for each study and gender separately
| Study | SDLP PBO (SD) | SDLP ALC (SD) | ΔSDLP (95% CI) | F |
| Dunlap’s ES | Improved/impaired | |
|---|---|---|---|---|---|---|---|---|
| Ramaekers et al. | Alla | 20.2 (4.0) | 23.2 (4.6) | 3.0 (0.9–5.2) | 8.9 | <0.01 | 0.69 | 00/08 |
| Vermeeren and O’Hanlon | All | 21.9 (5.7) | 25.5 (7.3) | 3.6 (1.9–5.3) | 19.0 | <0.001 | 0.52 | 02/15 |
| Male | 22.2 (5.6) | 25.3 (7.1) | 3.1 (−0.3–6.4) | – | NS | 0.47 | 02/06 | |
| Female | 21.6 (6.1) | 25.8 (7.8) | 4.1 (2.6–5.7) | 34.5 | <0.001 | 0.42 | 00/09 | |
| Ramaekers et al. | Alla | 22.3 (4.8) | 24.4 (3.4) | 2.0 (0.5–3.5) | 8.3 | <0.05 | 0.45 | 02/08 |
| Vermeeren et al. | All | 20.0 (3.6) | 22.3 (3.9) | 2.3 (1.5–3.1) | 37.3 | <0.001 | 0.59 | 00/10 |
| Male | 19.5 (4.4) | 21.1 (4.4) | 1.6 (0.4–2.9) | 8.9 | <0.05 | 0.37 | 00/03 | |
| Female | 20.5 (2.8) | 23.5 (3.3) | 3.0 (1.9–4.0) | 39.5 | <0.001 | 0.93 | 00/07 | |
| Vermeeren et al. | All | 17.7 (3.0) | 19.4 (3.7) | 1.7 (0.7–2.6) | 12.9 | <0.01 | 0.49 | 00/07 |
| Male | 18.0 (3.2) | 20.3 (4.2) | 2.3 (0.3–4.2) | 6.4 | <0.05 | 0.58 | 00/06 | |
| Female | 17.4 (2.7) | 18.5 (2.8) | 1.1 (0.6–1.5) | 24.3 | <0.001 | 0.40 | 00/01 | |
| Kuypers et al. | All | 20.6 (3.9) | 23.5 (4.0) | 2.9 (1.2–4.5) | 13.5 | <0.01 | 0.73 | 00/09 |
| Male | 20.2 (3.9) | 23.8 (3.8) | 3.6 (1.1–6.0) | 11.2 | <0.05 | 0.92 | 00/05 | |
| Female | 21.1 (4.0) | 23.3 (4.4) | 2.2 (−0.5–4.8) | – | NS | 0.51 | 00/04 | |
| van der Sluiszen et al. | All | 17.0 (2.6) | 19.4 (3.4) | 2.5 (1.7–3.2) | 46.7 | <0.001 | 0.72 | 00/12 |
| Male | 17.2 (2.2) | 18.9 (2.8) | 1.7 (0.6–2.8) | 11.5 | <0.01 | 0.63 | 00/03 | |
| Female | 16.8 (3.1) | 20.0 (4.0) | 3.2 (2.2–4.1) | 50.3 | <0.001 | 0.79 | 00/09 | |
| Schumacher et al. | All | 18.3 (4.1) | 20.7 (3.3) | 2.4 (1.2–3.6) | 18.4 | <0.05 | 0.61 | 00/10 |
| Male | 18.5 (4.5) | 20.5 (3.6) | 2.0 (0.5–3.6) | 8.1 | <0.05 | 0.47 | 00/06 | |
| Female | 17.9 (3.4) | 21.3 (2.7) | 3.4 (1.1–5.8) | 16.4 | <0.05 | 1.06 | 00/04 | |
| Schumacher | All | 19.7 (3.3) | 21.5 (3.2) | 1.9 (0.6–3.2) | 10.1 | <0.01 | 0.58 | 00/07 |
| Male | 19.2 (5.2) | 22.0 (3.9) | 2.8 (0.3–5.2) | 8.0 | <0.05 | 0.52 | 00/03 | |
| Female | 20.0 (1.6) | 21.3 (2.9) | 1.3 (−0.4–3.0) | – | NS | 0.48 | 00/04 | |
| Total | All 182 | 19.6 (4.3) | 22.1 (4.8) | 2.5 (2.0–2.9) | 132.8 | <0.001 | 0.54 | 04/86 |
| Male 75b | 19.2 (4.3) | 21.6 (4.8) | 2.4 (1.7–3.1) | 42.8 | <0.001 | 0.51 | 02/32b | |
| Female 73b | 19.2 (4.0) | 21.7 (5.0) | 2.5 (2.0–3.1) | 93.1 | <0.001 | 0.51 | 00/38b |
BAC blood alcohol concentration, PBO placebo, ALC alcohol, ES effect size, NS not significant
aNo gender data available
bGender data deviates from total, because no gender data were available of 34 participants
Fig. 3Overall mean change of standard deviation of lateral position (Δ SDLP, in centimeter) with 95% confidence interval (CI) and mean changes of SDLP with 95% CI of each individual study after alcohol reaching a blood alcohol concentration (BAC) of 0.5 g/L. The vertical black line is the clinically relevant cutoff point of 2.4 cm, as defined by Louwerens et al. (1987). Study 1: Ramaekers et al. 1992, Study 2: Vermeeren and O’Hanlon 1998, Study 3: Ramaekers et al. 2000, Study 4: Vermeeren et al. 2002a, Study 5: Vermeeren et al. 2002b, Study 6: Kuypers et al. 2006, Study 7: van der Sluiszen et al. 2016, Study 8: Schumacher et al. 2011, Study 9: Schumacher 2014
Fig. 4Individual and mean (horizontal lines) alcohol-placebo changes in driving performance as measured by the standard deviation of lateral position (SDLP). Change scores for each individual study are shown separately for males (squares) and females (triangles) and for individuals for whom gender data was missing (circles). Dotted lines show thresholds for impaired (changes above 2.4 cm) and improved driving (changes below −2.4 cm). Study 1: Ramaekers et al. 1992, Study 2: Vermeeren and O’Hanlon 1998, Study 3: Ramaekers et al. 2000, Study 4: Vermeeren et al. 2002a, Study 5: Vermeeren et al. 2002b, Study 6: Kuypers et al. 2006, Study 7: van der Sluiszen et al. 2016, Study 8: Schumacher et al. 2011, Study 9: Schumacher 2014